Micronized tanaproget and compositions containing same
The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.
1. A pharmaceutical composition comprising micronized tanaproget, or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate.
2. The composition according to claim 1 , wherein said tanaproget comprises about 0.08% to about 0.4% wt/wt of said composition.
3. The composition according to claim 1 which degrades less than about 4% over a period of greater than 1 month at temperatures at or greater than about 25° C. and a relative humidity at or greater than about 60%.
4. The composition according to claim 1 , wherein the particles of said micronized tanaproget are less than about 10 μm.
5. The composition according to claim 1 , wherein the particles of said composition are less than about 125 μm.
6. A pharmaceutical composition for oral administration comprising about 0.0875% wt/wt micronized tanaproget, about 56.31% wt/wt microcrystalline cellulose, about 6% wt/wt croscarmellose sodium, about 37.35% wt/wt anhydrous lactose, and about 0.25% wt/wt magnesium stearate.
7. A pharmaceutical composition for oral administration comprising about 0.35% wt/wt micronized tanaproget, about 56.23% wt/wt microcrystalline cellulose, about 6% wt/wt croscarmellose sodium, about 37.17% wt/wt anhydrous lactose, and about 0.25% wt/wt magnesium stearate.
8. A capsule comprising the composition of claim 1 .
9. A pharmaceutical kit comprising a daily dosage unit of said capsule of claim 8 .
10. The pharmaceutical kit according to claim 9 , comprising a single phase of a daily dosage of said composition over a 21, 28, 31, or 31-day cycle.
11. The pharmaceutical kit according to claim 10 , further comprising a placebo.
12. The composition according to claim 1 , comprising about 0.05 mg to about 1 mg of tanaproget.
13. A tablet comprising the composition of claim 1 .
14. A method of contraception, said method comprising administering the composition of claim 1 to a female patient.
15. A method of hormone replacement therapy, said method comprising administering the composition of claim 1 to a patient.
16. A method of treating uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostrate, said method comprising administering the composition of claim 1 to a patient.